CLINICAL_TRIALS
ClinicalTrials.gov record update
A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02949219
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:15.730427+00:00
- Published At
- 2020-01-10T00:00:00+00:00
- Record Updated At
- 2024-08-22
- Results Posted At
- 2020-01-10
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Metastatic Small Intestinal Adenocarcinoma", "Recurrent Small Intestinal Carcinoma", "Unresectable Small Intestinal Carcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-08-22"- protocolSection.identificationModule.nctId
"NCT02949219"- protocolSection.identificationModule.officialTitle
"A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-01-10"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.